Make it stand out.

In recent years, the pharmaceutical industry has seen a sharp increase in the number of specialty drugs receiving FDA approval, a trend that shows no signs of slowing down. This is largely driven by advancements in research and technology, which have enabled the development of treatments for complex and rare conditions that previously had no solutions. Today, more than half of newly approved drugs fall into the specialty category, and with this growth, specialty drug costs are expected to keep rising. Moreover, experts predict that specialty medications will account for nearly two-thirds of new drug launches over the next five years. 

Specialty drugs, while used by only 5% of the population, significantly drive overall drug spending. In 2021, specialty drug costs totaled $301 billion, reflecting a 43% increase since 2016. These medications accounted for 50% of total drug spending, demonstrating their substantial financial impact to the healtchare system. Addtionally, healthcare providers are  becoming more comfortable prescribing these drugs, and patients are more open to trying various treatment forms, such as injectables, which can provide additional benefits.

Given these trends and statistics, careful management of specialty therapies is more important than ever.

At MindfulRx, we are fully aware of the financial burden posed by the increasing cost of specialty medications. Our Specialty Management Program is designed to address these challenges with tailored strategies that meet the specific needs of health plans, providers, and other healthcare organizations.

Our program focuses on high-cost drugs by identifying clinically comparable alternatives that are both effective and more affordable. We leverage evidence-based data to ensure that any recommended alternatives meet safety and efficacy standards. By working closely with healthcare providers, we make sure that cost-saving alternatives do not compromise patient outcomes.

In addition, we tailor our initiatives to each plan’s formulary and provide robust patient support. Some critical therapeutic areas that can be impacted include biosimilars, hereditary